Parexel Announces Updates to Board of DirectorsDURHAM, N.C., March 05, 2025 (GLOBE NEWSWIRE) -- Parexel, one of the world's largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, today announced the appointment of Jeff Bernstein, Partner, Private Equity, Goldman Sachs Asset Management, and Co-Head, Goldman Sachs Healthcare Private Equity Investing, to its Board of Directors effective March 5, 2025. Mr. Bernstein succeeds Michael Bruun, Partner, Global Co-Head of Private Equity, Goldman Sachs Asset Management, as part of a planned rotation.
Parexel Names Keri Mattox Chief Business OfficerHealthcare executive to lead company’s business operations and growth strategy
Parexel’s Teri Karcher Named to 2024 PharmaVoice 100Chief Drug Development Officer and Executive Vice President, Head of Launch Excellence recognized for pioneering leadership in drug development
Parexel Strengthens Real World Research OfferingMike D’Ambrosio appointed as Senior Vice President, Global Head, Real World Research, reflecting the company’s commitment to an evidence-based approach in ensuring safety and efficacy in drug development efforts for customers worldwide
Parexel’s Near-Term Greenhouse Gas Reduction Targets Validated by Science Based Target Initiative (SBTi)DURHAM, N.C., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, today announced that its near-term science-based greenhouse gas reduction (GHG) targets have been validated by the Science Based Targets initiative (SBTi). SBTi validation is a recognition that is widely considered the gold standard for setting and reducing corporate GHG emissions. The company is one of the few global CROs with validated science-based targets.
Parexel Releases 2023 Environmental, Social and Governance ReportDURHAM, N.C., July 29, 2024 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, today announced the release of its 2023 Environmental, Social and Governance ("ESG") Report. The ESG Report is part of Parexel’s annual commitment to disclose and communicate the progress of its sustainability priorities, underscoring the company’s core values of putting Patients First and delivering With Heart™.
Parexel and Palantir Expand Collaboration to Accelerate Clinical Data Delivery and Power Clinical Outcomes for PatientsDURHAM, N.C. and DENVER, April 25, 2024 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, and Palantir Technologies Inc. (
NYSEPLTR) (Palantir), a leading builder of Artificial Intelligence (AI) systems, today announced a multi-year strategic partnership to leverage AI to help enhance and accelerate the delivery of safe and effective clinical trials for the world’s biopharmaceutical customers. Under the collaboration, Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform (AIP) to further power its clinical data platform, focused on driving clinical trial efficiency while maintaining the highest level of safety and regulatory rigor. Parexel is the first CRO working with Palantir in this capacity, building on the companies’ existing collaboration over the past year.
Parexel Named “Best Contract Research Organization” at 17th Annual Vaccine Industry Excellence (ViE) AwardsCompany recognized by a distinguished industry advisory board for its expertise and leadership in supporting the development of vaccines
Parexel Announces CEO Succession PlanChief Operating & Growth Officer Peyton Howell to succeed Jamie Macdonald effective May 15, 2024; Mr. Macdonald to retire as CEO and continue on the Board of Directors through Dec. 31, 2024
Parexel Appoints Susan R. Salka to Board of DirectorsMs. Salka brings more than 30 years of healthcare leadership and staffing expertise, including strong C-suite, financial and ESG expertise to advance the company’s Patients-first focus and growth initiatives
Parexel and Japanese Foundation for Cancer Research Announce Strategic AllianceCollaboration streamlines patient access to oncology clinical trials; further expands Parexel's Site Alliance Network across Asia/Pacific
Parexel Named “Best Contract Research Organization” at 19th Annual Scrip AwardsCompany recognized with prestigious industry award by a distinguished panel of life science industry executives
Parexel Named 2023 Healthcare Businesswomen’s Association ACE Award HonoreeAward reflects company’s ongoing commitment to advancing women in leadership and maintaining a gender-equitable culture
Global Investigative Sites Recognize Parexel with the 2023 Society for Clinical Research Sites Eagle AwardPrestigious industry recognition reflects company’s commitment to the development of strong site relationships in support of patients
Parexel’s Amy McKee, M.D. Named to 2023 PharmaVoice 100Company’s Chief Medical Officer and FDA veteran receives distinguished award for notable contributions to clinical research
Parexel Appoints Gwyn Bebb, BM, BCh., Ph.D., to Lead Oncology Clinical DevelopmentAppointment further strengthens company’s expertise in fastest-growing therapeutic area to meet patient need
Parexel and Partex Announce Innovative Alliance Leveraging Artificial Intelligence and Big Data to Accelerate Drug Discovery and DevelopmentCollaboration combines clinical research expertise with artificial intelligence capabilities to help drug developers better understand the probability of clinical success for their assets
Parexel Announces Updates to Board of DirectorsDURHAM, N.C., June 23, 2023 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, today announced the appointments of Michael Bruun, Partner, Global co-Head of Private Equity, Goldman Sachs Asset Management, and John Groetelaars, Non-Executive Director and former Interim CEO of Dentsply Sirona and former President & CEO at Hillrom, to its Board of Directors. The appointments of Mr. Bruun and Mr. Groetelaars are effective June 23, 2023. Mr. Bruun succeeds Jo Natauri, Partner and Global Head of Healthcare Investing in the Asset Management Division of Goldman Sachs, who will be focusing on entrepreneurial pursuits following a successful 25-year career, 17 of which were with Goldman Sachs.
Parexel Rated “Top CRO to Work With” in 2023 WCG CenterWatch Global Site Relationship Benchmark Survey for Second Straight TimeCompany receives highest average rating across all 26 performance attributes out of 34 CROs included in survey and highest Net Promoter Score demonstrating likelihood to be recommended to colleagues
Parexel Appoints Scott Smith, M.D., Ph.D. as New Head of HematologyAddition of new therapeutic expert reflects company’s commitment to drug development in hematology
Parexel Introduces Expert Series – New Medicines, Novel InsightsNew evidence-based reports offer timely analysis and actionable guidance to drug developers bringing critical new therapies to market
Parexel Teams with MyEyeDr. to Increase Patient Access and Participation in Ophthalmology Clinical TrialsNew collaboration leverages MyEyeDr.’s 850+ offices across the US to refer patients into ophthalmology and other therapeutic area clinical trials, expands Parexel’s Community Alliance Network to bring trials to patients where they are
Parexel Opens Clinical Trial Supplies and Logistics Depot in Suzhou, ChinaNew depot offers local and international biopharmaceutical customers timely access to supplies and medications for clinical trial sites and patientsto accelerate clinical trials in the region
